Qingzao Jiufeitang is a famous classical formula for treating lung injury caused by warm and dryness， included in the Catalogue of Ancient Famous Classical Formulas（The First Batch）. By systematically organizing ancient and modern literature on this formula， this study analyzed and verified the origin， medicinal composition， original plants and processing， dosage and decoction method， efficacy and application of this formula. According to the research， Qingzao Jiufeitang was first recorded in Yimen Falyu in the Qing dynasty， and its creation was mainly inspired by the Ming dynasty physician MIAO Xiyong's idea of the moisturizing drugs with sweet flavour and cold nature. Based on the 2020 edition of the Pharmacopoeia of the People's Republic of China（hereinafter referred to as the Chinese Pharmacopoeia） and the textual research results of modern scholars on traditional Chinese herbal medicines， the botanical sources and processing methods of the herbs in this formula are basically clarified. Among them， Mori Folium， Gypsum Fibrosum， Ginseng Radix et Rhizoma， Sesami Semen Nigrum， Asini Corii Colla， Ophiopogonis Radix and Eriobotryae Folium are consistent with the 2020 edition of the Chinese Pharmacopoeia. The primary source of Glycyrrhizae Radix et Rhizoma is the dried roots and rhizomes of Glycyrrhiza uralensis， family Leguminosae， while the primary source of Armeniacae Semen Amarum is the dried mature seeds of Prunus armeniaca， family Rosaceae. It is recommended to use Gypsum Ustum， stir-fried Sesami Semen Nigrum， stir-fried Armeniacae Semen Amarum， Asini Corii Colla bead， and honey-fried Eriobotryae Folium， and the rest of the raw products. According to the conversion of ancient and modern doses， the recommended dosages are 11.19 g for Mori Folium， 9.33 g for Gypsum Fibrosum， 3.73 g for Glycyrrhizae Radix et Rhizoma， 2.61 g for Ginseng Radix et Rhizoma， 3.73 g for Sesami Semen Nigrum， 4.48 g for Ophiopogonis Radix， 2.61 g for Armeniacae Semen Amarum， 3.73 g for Eriobotryae Folium. The decoction method is to add 300 mL of water， decoct it down to 180 mL， remove the residue， and then add 2.98 g of Asini Corii Colla into the decoction. Take it warm after meals， two to three times a day. Qingzao Jiufeitang has the effects of clearing dryness and moistening the lungs， nourishing Yin and invigorating Qi. In ancient times， it was mainly used to treat stagnation and depression of various Qi， as well as paralysis， asthma and vomiting. In modern clinical practice， it is mostly used to treat diseases in respiratory system， otolaryngology， skin system and digestive system caused by warm-dry impairing lung， deficiency of both Qi and Yin. The above research results can provide a reference for the later development of Qingzao Jiufeitang.

Objective:To investigate the therapeutic effectiveness and related factors of fertility preservation therapy(referred to as conservation therapy)using Levonorgestre-releasing intrauterine system(LNG-IUS)com-bined with Metformin in patients with atypical endometrial hyperplasia and early endometrial cancer.Methods:A retrospective analysis was conducted on the clinical data of 41 patients with atypical endometrial hyperplasia and 11 patients with early endometrial cancer who required fertility preservation therapy and admitted to Shenyang Women and Children's Hospital from January 1,2015 to December 30,2021.According to different treatment methods,they were divided into a study group(26 cases,LNG-IUS+metformin)and a control group(26 cases,high efficiency progesterone+metformin).Regularly review endometrial pathology and analyze the differences in complete remission rate,recurrence rate,and pregnancy outcomes between the two groups.Univariate Logistic regression was used to analyze the factors affecting complete remission,recurrence,and pregnancy outcomes in those patients.Results:There was no statistically significant difference in general clinical data between the two groups(P＞0.05).Compared with the control group,the study group had higher complete remission rate,shorter average complete remission time,less recurrence rate,and higher live birth rate,with a statistically significant be-tween the two groups(P＜0.05).Logistic regression analysis found that body mass index(BMI)≥30 kg/m2was a risk factor for complete remission(P＜0.05);BMI ≥30 kg/m2 and patients with diabetes or insulin resistance were the risk factors for recurrence after treatment(P＜0.05);BMI≥30 kg/m2 and diseases associated with fe-male reproductive system were the risk factors for pregnancy after preserving fertility therapy(P＜0.05).Conclu-sions:LNG-IUS combined with metformin has a more satisfactory therapeutic effect and pregnancy outcomes,compared to high efficiency progesterone combined with metformin in preserving fertility therapy.At the same time,BMI＜30 kg/m2 can increase the complete remission rate,reduce the recurrence rate after cure,and in-crease the pregnancy rate after preserving fertility therapy.

177Lu-prostate specific membrane antigen(PSMA)radio-ligand therapy has been approved abroad for advanced prostate cancer and has been in several clinical trials in China.Based on domestic clinical practice and experimental data and referred to international experience and viewpoints,the expert group forms a consensus on the clinical application of 177Lu-PSMA radio-ligand therapy in prostate cancer to guide clinical practice.

Objective:To investigate the incidence of radiation pneumonitis (RP) induced by 125I seed implantation for the treatment of malignant lung tumors and analyze related dosimetric parameters. Methods:A retrospective analysis was conducted on 31 cases of malignant lung tumors treated with 125I seed implantation from January 2017 to December 2022 at Hebei Provincial Tumor Radioactive Seeds Implantation Diagnosis and Treatment Center. These cases consisted of eight patients with squamous cell carcinoma, 10 patients with adenocarcinoma, and 13 patients with metastatic cancer in other sites. At 1-6 months after treatment, these patients received postoperative chest CT scans, with the efficacy evaluated based on the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), including the objective response rate (ORR) and the disease control rate (DCR). The efficacy of RP was evaluated using the Radiation Therapy Oncology Group (RTOG) criteria. Postoperative dosimetric parameters, including D90 (minimum peripheral dose received by 90% of the target volume), V8 (percentage of lung volume receiving 8 Gy), V32 (percentage of lung volume receiving 32 Gy), and Dmean (mean radiation dose) of the affected lung, were statistically analyzed. The relationships of the RP occurrence with postoperative D90, V8, V32, and Dmean were analyzed by comparison with relevant external radiotherapy data, to identify the parameters that are correlated closely with RP occurrence. Results:All the patients underwent successful surgeries. The postoperative efficacy evaluation after six months showed complete response (CR) in 11 cases, partial response (PR) in 11 cases, stable disease (SD) in eight cases, and progressive disease (PD) in one case, with an overall response rate (ORR) of 71.0%, and a disease control rate (DCR) of 96.8%. Three patients suffered RP, with an incidence rate of 9.7%. Postoperative V8, V32, and Dmean could not serve as predictive indicators for RP. Follow-up observation revealed that three RP cases (3/5) exhibited postoperative D90 exceeding 170 Gy and no RP cases (0/26) showed postoperative D90 below 170 Gy. Conclusions:In the treatment of malignant lung tumors with 125I seed implantation, there is a certain correlation between RP and postoperative D90, while there is no correlation between it and V8, V32, and Dmean.

Objective:To investigate the therapeutic effectiveness and related factors of fertility preservation therapy(referred to as conservation therapy)using Levonorgestre-releasing intrauterine system(LNG-IUS)com-bined with Metformin in patients with atypical endometrial hyperplasia and early endometrial cancer.Methods:A retrospective analysis was conducted on the clinical data of 41 patients with atypical endometrial hyperplasia and 11 patients with early endometrial cancer who required fertility preservation therapy and admitted to Shenyang Women and Children's Hospital from January 1,2015 to December 30,2021.According to different treatment methods,they were divided into a study group(26 cases,LNG-IUS+metformin)and a control group(26 cases,high efficiency progesterone+metformin).Regularly review endometrial pathology and analyze the differences in complete remission rate,recurrence rate,and pregnancy outcomes between the two groups.Univariate Logistic regression was used to analyze the factors affecting complete remission,recurrence,and pregnancy outcomes in those patients.Results:There was no statistically significant difference in general clinical data between the two groups(P＞0.05).Compared with the control group,the study group had higher complete remission rate,shorter average complete remission time,less recurrence rate,and higher live birth rate,with a statistically significant be-tween the two groups(P＜0.05).Logistic regression analysis found that body mass index(BMI)≥30 kg/m2was a risk factor for complete remission(P＜0.05);BMI ≥30 kg/m2 and patients with diabetes or insulin resistance were the risk factors for recurrence after treatment(P＜0.05);BMI≥30 kg/m2 and diseases associated with fe-male reproductive system were the risk factors for pregnancy after preserving fertility therapy(P＜0.05).Conclu-sions:LNG-IUS combined with metformin has a more satisfactory therapeutic effect and pregnancy outcomes,compared to high efficiency progesterone combined with metformin in preserving fertility therapy.At the same time,BMI＜30 kg/m2 can increase the complete remission rate,reduce the recurrence rate after cure,and in-crease the pregnancy rate after preserving fertility therapy.

Objective:To investigate the therapeutic effectiveness and related factors of fertility preservation therapy(referred to as conservation therapy)using Levonorgestre-releasing intrauterine system(LNG-IUS)com-bined with Metformin in patients with atypical endometrial hyperplasia and early endometrial cancer.Methods:A retrospective analysis was conducted on the clinical data of 41 patients with atypical endometrial hyperplasia and 11 patients with early endometrial cancer who required fertility preservation therapy and admitted to Shenyang Women and Children's Hospital from January 1,2015 to December 30,2021.According to different treatment methods,they were divided into a study group(26 cases,LNG-IUS+metformin)and a control group(26 cases,high efficiency progesterone+metformin).Regularly review endometrial pathology and analyze the differences in complete remission rate,recurrence rate,and pregnancy outcomes between the two groups.Univariate Logistic regression was used to analyze the factors affecting complete remission,recurrence,and pregnancy outcomes in those patients.Results:There was no statistically significant difference in general clinical data between the two groups(P＞0.05).Compared with the control group,the study group had higher complete remission rate,shorter average complete remission time,less recurrence rate,and higher live birth rate,with a statistically significant be-tween the two groups(P＜0.05).Logistic regression analysis found that body mass index(BMI)≥30 kg/m2was a risk factor for complete remission(P＜0.05);BMI ≥30 kg/m2 and patients with diabetes or insulin resistance were the risk factors for recurrence after treatment(P＜0.05);BMI≥30 kg/m2 and diseases associated with fe-male reproductive system were the risk factors for pregnancy after preserving fertility therapy(P＜0.05).Conclu-sions:LNG-IUS combined with metformin has a more satisfactory therapeutic effect and pregnancy outcomes,compared to high efficiency progesterone combined with metformin in preserving fertility therapy.At the same time,BMI＜30 kg/m2 can increase the complete remission rate,reduce the recurrence rate after cure,and in-crease the pregnancy rate after preserving fertility therapy.

Objective:To investigate the therapeutic effectiveness and related factors of fertility preservation therapy(referred to as conservation therapy)using Levonorgestre-releasing intrauterine system(LNG-IUS)com-bined with Metformin in patients with atypical endometrial hyperplasia and early endometrial cancer.Methods:A retrospective analysis was conducted on the clinical data of 41 patients with atypical endometrial hyperplasia and 11 patients with early endometrial cancer who required fertility preservation therapy and admitted to Shenyang Women and Children's Hospital from January 1,2015 to December 30,2021.According to different treatment methods,they were divided into a study group(26 cases,LNG-IUS+metformin)and a control group(26 cases,high efficiency progesterone+metformin).Regularly review endometrial pathology and analyze the differences in complete remission rate,recurrence rate,and pregnancy outcomes between the two groups.Univariate Logistic regression was used to analyze the factors affecting complete remission,recurrence,and pregnancy outcomes in those patients.Results:There was no statistically significant difference in general clinical data between the two groups(P＞0.05).Compared with the control group,the study group had higher complete remission rate,shorter average complete remission time,less recurrence rate,and higher live birth rate,with a statistically significant be-tween the two groups(P＜0.05).Logistic regression analysis found that body mass index(BMI)≥30 kg/m2was a risk factor for complete remission(P＜0.05);BMI ≥30 kg/m2 and patients with diabetes or insulin resistance were the risk factors for recurrence after treatment(P＜0.05);BMI≥30 kg/m2 and diseases associated with fe-male reproductive system were the risk factors for pregnancy after preserving fertility therapy(P＜0.05).Conclu-sions:LNG-IUS combined with metformin has a more satisfactory therapeutic effect and pregnancy outcomes,compared to high efficiency progesterone combined with metformin in preserving fertility therapy.At the same time,BMI＜30 kg/m2 can increase the complete remission rate,reduce the recurrence rate after cure,and in-crease the pregnancy rate after preserving fertility therapy.

Objective:To investigate the therapeutic effectiveness and related factors of fertility preservation therapy(referred to as conservation therapy)using Levonorgestre-releasing intrauterine system(LNG-IUS)com-bined with Metformin in patients with atypical endometrial hyperplasia and early endometrial cancer.Methods:A retrospective analysis was conducted on the clinical data of 41 patients with atypical endometrial hyperplasia and 11 patients with early endometrial cancer who required fertility preservation therapy and admitted to Shenyang Women and Children's Hospital from January 1,2015 to December 30,2021.According to different treatment methods,they were divided into a study group(26 cases,LNG-IUS+metformin)and a control group(26 cases,high efficiency progesterone+metformin).Regularly review endometrial pathology and analyze the differences in complete remission rate,recurrence rate,and pregnancy outcomes between the two groups.Univariate Logistic regression was used to analyze the factors affecting complete remission,recurrence,and pregnancy outcomes in those patients.Results:There was no statistically significant difference in general clinical data between the two groups(P＞0.05).Compared with the control group,the study group had higher complete remission rate,shorter average complete remission time,less recurrence rate,and higher live birth rate,with a statistically significant be-tween the two groups(P＜0.05).Logistic regression analysis found that body mass index(BMI)≥30 kg/m2was a risk factor for complete remission(P＜0.05);BMI ≥30 kg/m2 and patients with diabetes or insulin resistance were the risk factors for recurrence after treatment(P＜0.05);BMI≥30 kg/m2 and diseases associated with fe-male reproductive system were the risk factors for pregnancy after preserving fertility therapy(P＜0.05).Conclu-sions:LNG-IUS combined with metformin has a more satisfactory therapeutic effect and pregnancy outcomes,compared to high efficiency progesterone combined with metformin in preserving fertility therapy.At the same time,BMI＜30 kg/m2 can increase the complete remission rate,reduce the recurrence rate after cure,and in-crease the pregnancy rate after preserving fertility therapy.

Objective:To investigate the therapeutic effectiveness and related factors of fertility preservation therapy(referred to as conservation therapy)using Levonorgestre-releasing intrauterine system(LNG-IUS)com-bined with Metformin in patients with atypical endometrial hyperplasia and early endometrial cancer.Methods:A retrospective analysis was conducted on the clinical data of 41 patients with atypical endometrial hyperplasia and 11 patients with early endometrial cancer who required fertility preservation therapy and admitted to Shenyang Women and Children's Hospital from January 1,2015 to December 30,2021.According to different treatment methods,they were divided into a study group(26 cases,LNG-IUS+metformin)and a control group(26 cases,high efficiency progesterone+metformin).Regularly review endometrial pathology and analyze the differences in complete remission rate,recurrence rate,and pregnancy outcomes between the two groups.Univariate Logistic regression was used to analyze the factors affecting complete remission,recurrence,and pregnancy outcomes in those patients.Results:There was no statistically significant difference in general clinical data between the two groups(P＞0.05).Compared with the control group,the study group had higher complete remission rate,shorter average complete remission time,less recurrence rate,and higher live birth rate,with a statistically significant be-tween the two groups(P＜0.05).Logistic regression analysis found that body mass index(BMI)≥30 kg/m2was a risk factor for complete remission(P＜0.05);BMI ≥30 kg/m2 and patients with diabetes or insulin resistance were the risk factors for recurrence after treatment(P＜0.05);BMI≥30 kg/m2 and diseases associated with fe-male reproductive system were the risk factors for pregnancy after preserving fertility therapy(P＜0.05).Conclu-sions:LNG-IUS combined with metformin has a more satisfactory therapeutic effect and pregnancy outcomes,compared to high efficiency progesterone combined with metformin in preserving fertility therapy.At the same time,BMI＜30 kg/m2 can increase the complete remission rate,reduce the recurrence rate after cure,and in-crease the pregnancy rate after preserving fertility therapy.

Objective:To investigate the therapeutic effectiveness and related factors of fertility preservation therapy(referred to as conservation therapy)using Levonorgestre-releasing intrauterine system(LNG-IUS)com-bined with Metformin in patients with atypical endometrial hyperplasia and early endometrial cancer.Methods:A retrospective analysis was conducted on the clinical data of 41 patients with atypical endometrial hyperplasia and 11 patients with early endometrial cancer who required fertility preservation therapy and admitted to Shenyang Women and Children's Hospital from January 1,2015 to December 30,2021.According to different treatment methods,they were divided into a study group(26 cases,LNG-IUS+metformin)and a control group(26 cases,high efficiency progesterone+metformin).Regularly review endometrial pathology and analyze the differences in complete remission rate,recurrence rate,and pregnancy outcomes between the two groups.Univariate Logistic regression was used to analyze the factors affecting complete remission,recurrence,and pregnancy outcomes in those patients.Results:There was no statistically significant difference in general clinical data between the two groups(P＞0.05).Compared with the control group,the study group had higher complete remission rate,shorter average complete remission time,less recurrence rate,and higher live birth rate,with a statistically significant be-tween the two groups(P＜0.05).Logistic regression analysis found that body mass index(BMI)≥30 kg/m2was a risk factor for complete remission(P＜0.05);BMI ≥30 kg/m2 and patients with diabetes or insulin resistance were the risk factors for recurrence after treatment(P＜0.05);BMI≥30 kg/m2 and diseases associated with fe-male reproductive system were the risk factors for pregnancy after preserving fertility therapy(P＜0.05).Conclu-sions:LNG-IUS combined with metformin has a more satisfactory therapeutic effect and pregnancy outcomes,compared to high efficiency progesterone combined with metformin in preserving fertility therapy.At the same time,BMI＜30 kg/m2 can increase the complete remission rate,reduce the recurrence rate after cure,and in-crease the pregnancy rate after preserving fertility therapy.